UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

SAREPTA THERAPEUTICS, INC.,
Petitioners,

v.

GENZYME CORPORATION,
Patent Owner.

---

Case No. IPR2026-00167
Patent No. 11,698,377

---

**PATENT OWNER'S MANDATORY NOTICES**

# MANDATORY NOTICES UNDER 37 C.F.R § 42.8

Pursuant to 37 C.F.R. § 42.8, Patent Owner Genzyme Corporation states as follows:

## I. Real Party-in-Interest Under 37 CFR § 42.8(b)(1)

Patent Owner Genzyme Corporation is a direct wholly-owned subsidiary of Aventis Inc. Genzyme Corporation and Aventis Inc. are indirect wholly-owned subsidiaries of Sanofi. Sanofi, the ultimate parent company of Genzyme Corporation, Genzyme Corporation, and Aventis, Inc. are the real parties-in-interest as Patent Owner.

## II. Related Matters Under 37 CFR § 42.8(b)(2)

### A. U.S. District Court for District of Delaware Related Matters

The following pending district court litigation may affect or be affected by this proceeding: *Genzyme Corp v. Sarepta Therapeutics, Inc.*, C.A. No. 24-cv-00882-RGA (D. Del.).

### B. Patent Trial and Appeal Board Co-Pending Matters

Concurrently with the present Petition, Petitioner filed an *Inter Partes* Review ("IPR") Petition challenging the patentability of certain claims of U.S. Patent No. 12,298,313 in IPR2026-00166 and U.S. Patent No. 12,123,880 in IPR2026-00168. Those IPRs may affect indirectly or may be affected by the decision

in this proceeding since the patents are related and involved in the Delaware litigation (*supra* § II.A).

## III. Lead and Backup Counsel Under 37 C.F.R. § 42.8(b)(3)

Patent Owner identifies the following designation of counsel:

| Lead Counsel | Back-Up Counsel |
|---|---|
| Amanda K. Antons, Reg. No. 65,236<br>Dechert LLP<br>230 Northgate Street #209<br>Lake Forest, IL 60045<br>Tel: 312-646-5822<br>amanda.antons@dechert.com | Katherine A. Helm, *pro hac vice* to be applied for<br>Dechert LLP<br>Three Bryant Park<br>1095 Avenue of the Americas<br>New York, NY 10036-6797<br>Tel: 212-698-3500<br>khelm@dechert.com<br><br>Blaine M. Hackman, Reg. No. 67,479<br>Dechert LLP<br>Three Bryant Park<br>1095 Avenue of the Americas<br>New York, NY 10036-6797<br>Tel: 212-698-3500<br>blaine.hackman@dechert.com |

Pursuant to 37 C.F.R. § 42.10(b), Patent Owner is filing a power of attorney concurrently with this mandatory notice.

## IV. Service Information Under 37 C.F.R. § 42.8(b)(4)

Patent Owner may be served at the above addresses for lead and back-up counsel. Pursuant to 37 C.F.R. § 42.6(e)(1), Patent Owner consents to electronic service by email.

Date: December 23, 2025

/*Blaine M. Hackman*/

Blaine M. Hackman, Reg. No. 67,479
Dechert LLP
Three Bryant Park
1095 Avenue of the Americas
New York, NY 10036-6797
Tel: 212-698-3500
Fax: 212-698-3599
blaine.hackman@dechert.com
*Counsel for Patent Owner,*
*Genzyme Corporation*

# CERTIFICATE OF SERVICE

Pursuant to 37 C.F.R. § 42.6(e), I certify that today in

*Sarepta Therapeutics, Inc., v. Genzyme Corporation*, IPR2026-00167

I caused to be served a copy of:

**PATENT OWNER'S MANDATORY NOTICES**

upon:

Sarepta Therapeutics, Inc. c/o:

robertwilson@quinnemanuel.com
annetoker@quinnemanuel.com
jimglass@quinnemanuel.com

via:

electronic service to the email addresses above.

Date: December 23, 2025

/*Blaine M. Hackman*/

Blaine M. Hackman, Reg. No. 67,479
Dechert LLP
Three Bryant Park
1095 Avenue of the Americas
New York, NY 10036-6797
Tel: 212-698-3500
Fax: 212-698-3599
blaine.hackman@dechert.com
*Counsel for Patent Owner,*
*Genzyme Corporation*